The US Food and Drug Administration has approved Roche/Shionogi & Co’s Xofluza for the treatment of acute uncomplicated flu, opening the door to the first new antiviral with a novel mechanism of action in nearly 20 years.Original Article
You may also like
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.